Clinical Trials Logo

Clinical Trial Summary

Multiple myeloma (MM) is a rare cancer caused by abnormal survival of plasma cells (blood cells). Most trial participants with MM relapse (cancer has come back) or become non- responsive to treatment and remission gets shorter after each line of treatment. This is a study to assess t(11;14) and BCL2 expression in adult participants with newly diagnosed and relapsed/refractory (R/R) MM. Approximately 500 adult participants with newly confirmed or relapsed/refractory (R/R) multiple myeloma (MM) will be enrolled in around 15-20 countries. Participants will receive standard of care while participating in this study. No drug will be administered as a part of this study. Participants will attend regular visits during the course of the study at a hospital or clinic and will be asked to provide bone marrow and blood samples.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04721002
Study type Observational
Source AbbVie
Contact
Status Completed
Phase
Start date July 7, 2021
Completion date September 30, 2023

See also
  Status Clinical Trial Phase
Completed NCT02265731 - Study Evaluating Venetoclax in Subjects With Hematological Malignancies Phase 1/Phase 2
Recruiting NCT05442580 - CART-38 in Adult AML and MM Patients Phase 1
Terminated NCT04178902 - A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory (R/R) Multiple Myeloma Phase 1
Completed NCT02920697 - Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma Phase 1
Recruiting NCT05908409 - A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies Phase 1/Phase 2
Active, not recruiting NCT04702425 - VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma) Phase 1
Completed NCT00710528 - Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies Phase 1
Active, not recruiting NCT02240537 - Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer Phase 1
Active, not recruiting NCT02203643 - Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma. Phase 2
Completed NCT02211014 - An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma Phase 1
Recruiting NCT04649073 - Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma Phase 1/Phase 2
Active, not recruiting NCT04123418 - A Study of WVT078 in Patients With Multiple Myeloma (MM) Phase 1
Recruiting NCT03018405 - A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications Phase 1/Phase 2
Terminated NCT01663766 - Phase I Study of Milatuzumab for Graft Versus Host Disease Phase 1
Completed NCT01919086 - Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma Phase 2
Withdrawn NCT05513612 - Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies Phase 1
Completed NCT01413568 - Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies Phase 1/Phase 2
Completed NCT00889798 - Tumor Registry of Lymphatic Neoplasia